Sysmex (6869.T) Stock Price

Sysmex Price

JPX·CLOSED
1,897.50JPY+16.00 (+0.85 %)
Market closed

Revenue has compounded at 9.7% per year over the past 19 years to 508.64 B JPY. Earnings per share have grown at 10.9% per year over the last 19 years. Sysmex's net margin stands at 10.6%, broadly stable from 10.5% several years earlier. Sysmex currently offers a dividend yield of about 1.84%. The payout ratio is around 42% of earnings. Analysts set a median price target of 2,320.50 JPY, implying 22.3% above the current price. Of 21 analysts, 16 rate the stock a buy — an overall Buy consensus. The stock trades about 48% above its 52-week low.

Sysmex stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sysmex over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sysmex stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sysmex's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sysmex Stock Price History
DateSysmex Price
8/19/20261,897.50 JPY
8/18/20261,881.50 JPY
8/17/20261,866.00 JPY
8/14/20261,918.50 JPY
8/13/20261,888.50 JPY
8/12/20261,954.50 JPY
8/10/20261,969.00 JPY
8/7/20261,651.50 JPY
8/6/20261,621.50 JPY
8/5/20261,628.00 JPY
8/4/20261,610.50 JPY
8/3/20261,568.00 JPY
7/31/20261,599.00 JPY
7/30/20261,659.50 JPY
7/29/20261,672.50 JPY
7/28/20261,635.50 JPY
7/27/20261,603.00 JPY
7/24/20261,530.00 JPY
7/23/20261,511.00 JPY
7/22/20261,549.00 JPY
7/21/20261,630.00 JPY
7/17/20261,628.00 JPY
7/16/20261,551.00 JPY
7/15/20261,539.00 JPY
7/14/20261,571.00 JPY
7/13/20261,537.50 JPY
7/10/20261,538.00 JPY
7/9/20261,508.50 JPY
7/8/20261,590.50 JPY
7/7/20261,565.00 JPY
7/6/20261,588.00 JPY
7/3/20261,538.50 JPY
7/2/20261,522.00 JPY
7/1/20261,469.00 JPY
6/30/20261,466.00 JPY
6/29/20261,481.00 JPY
6/26/20261,449.00 JPY
6/25/20261,411.50 JPY
6/24/20261,381.50 JPY
6/23/20261,401.50 JPY
6/22/20261,389.50 JPY
6/19/20261,359.50 JPY
6/18/20261,389.50 JPY
6/17/20261,420.00 JPY
6/16/20261,420.50 JPY
6/15/20261,426.50 JPY
6/12/20261,407.50 JPY
6/11/20261,441.00 JPY
6/10/20261,467.00 JPY
6/9/20261,467.50 JPY
6/8/20261,463.00 JPY
6/5/20261,503.00 JPY
6/4/20261,496.00 JPY
6/3/20261,476.00 JPY
6/2/20261,439.50 JPY
6/1/20261,453.50 JPY
5/29/20261,419.00 JPY
5/28/20261,382.00 JPY
5/27/20261,409.50 JPY
5/26/20261,366.50 JPY
5/25/20261,383.50 JPY
5/22/20261,402.00 JPY
5/21/20261,375.00 JPY
5/20/20261,368.00 JPY
5/19/20261,403.50 JPY
5/18/20261,381.50 JPY
5/15/20261,297.00 JPY
5/14/20261,335.00 JPY
5/13/20261,342.00 JPY
5/12/20261,303.00 JPY
5/11/20261,325.00 JPY
5/8/20261,350.00 JPY
5/7/20261,319.00 JPY
5/1/20261,331.50 JPY
4/30/20261,378.00 JPY
4/28/20261,379.00 JPY
4/27/20261,400.00 JPY
4/24/20261,396.00 JPY
4/23/20261,385.00 JPY
4/22/20261,410.00 JPY
4/21/20261,420.50 JPY
4/20/20261,437.50 JPY
4/17/20261,437.00 JPY
4/16/20261,428.50 JPY
4/15/20261,432.00 JPY
4/14/20261,397.00 JPY
4/13/20261,385.50 JPY
4/10/20261,388.00 JPY
4/9/20261,406.50 JPY
4/8/20261,451.00 JPY
4/7/20261,425.50 JPY
4/6/20261,413.50 JPY
4/3/20261,430.00 JPY
4/2/20261,426.00 JPY
4/1/20261,430.00 JPY
3/31/20261,368.50 JPY
3/30/20261,344.50 JPY
3/27/20261,402.00 JPY
3/26/20261,365.00 JPY
3/25/20261,350.00 JPY
3/24/20261,356.00 JPY
3/23/20261,344.00 JPY
3/19/20261,385.00 JPY
3/18/20261,398.50 JPY
3/17/20261,370.00 JPY
3/16/20261,399.50 JPY
3/13/20261,403.50 JPY
3/12/20261,406.50 JPY
3/11/20261,452.00 JPY
3/10/20261,510.50 JPY
3/9/20261,555.50 JPY
3/6/20261,541.00 JPY
3/5/20261,419.00 JPY
3/4/20261,420.50 JPY
3/3/20261,465.50 JPY
3/2/20261,474.50 JPY
2/27/20261,472.00 JPY
2/26/20261,402.00 JPY
2/25/20261,381.50 JPY
2/24/20261,362.50 JPY
2/20/20261,338.50 JPY
2/19/20261,331.50 JPY
2/18/20261,281.50 JPY
2/17/20261,280.00 JPY
2/16/20261,325.00 JPY
2/13/20261,301.00 JPY
2/12/20261,584.00 JPY
2/10/20261,531.50 JPY
2/9/20261,520.50 JPY
2/6/20261,494.50 JPY
2/5/20261,492.00 JPY
2/4/20261,474.00 JPY
2/3/20261,471.50 JPY
2/2/20261,464.00 JPY
1/30/20261,467.00 JPY
1/29/20261,440.00 JPY
1/28/20261,462.50 JPY
1/27/20261,479.50 JPY
1/26/20261,518.50 JPY
1/23/20261,564.50 JPY
1/22/20261,539.50 JPY
1/21/20261,554.50 JPY
1/20/20261,580.00 JPY
1/19/20261,578.50 JPY
1/16/20261,569.50 JPY
1/15/20261,600.00 JPY
1/14/20261,608.00 JPY
1/13/20261,590.50 JPY
1/9/20261,577.00 JPY
1/8/20261,567.00 JPY
1/7/20261,582.00 JPY
1/6/20261,572.00 JPY
1/5/20261,534.50 JPY
12/30/20251,542.50 JPY
12/29/20251,550.00 JPY
12/26/20251,545.00 JPY
12/25/20251,550.50 JPY
12/24/20251,558.00 JPY
12/23/20251,578.50 JPY
12/22/20251,553.00 JPY
12/19/20251,561.50 JPY
12/18/20251,560.50 JPY
12/17/20251,522.50 JPY
12/16/20251,525.00 JPY
12/15/20251,515.00 JPY
12/12/20251,463.50 JPY
12/11/20251,480.50 JPY
12/10/20251,473.00 JPY
12/9/20251,467.00 JPY
12/8/20251,448.50 JPY
12/5/20251,458.50 JPY
12/4/20251,486.00 JPY
12/3/20251,454.00 JPY
12/2/20251,461.00 JPY
12/1/20251,445.00 JPY
11/28/20251,486.00 JPY
11/27/20251,505.00 JPY
11/26/20251,537.50 JPY
11/25/20251,566.00 JPY
11/21/20251,558.50 JPY
11/20/20251,497.00 JPY
11/19/20251,502.00 JPY
11/18/20251,513.50 JPY
11/17/20251,530.00 JPY
11/14/20251,565.00 JPY
11/13/20251,588.50 JPY
11/12/20251,616.00 JPY
11/11/20251,630.00 JPY
11/10/20251,668.50 JPY
11/7/20251,637.50 JPY
11/6/20251,610.00 JPY
11/5/20251,707.00 JPY
11/4/20251,706.50 JPY
10/31/20251,727.00 JPY
10/30/20251,724.50 JPY
10/29/20251,733.50 JPY
10/28/20251,784.00 JPY
10/27/20251,805.50 JPY
10/24/20251,800.00 JPY
10/23/20251,829.00 JPY
10/22/20251,840.00 JPY
10/21/20251,823.00 JPY
10/20/20251,821.50 JPY
10/17/20251,803.50 JPY
10/16/20251,786.00 JPY
10/15/20251,769.50 JPY
10/14/20251,777.00 JPY
10/10/20251,883.00 JPY
10/9/20251,868.50 JPY
10/8/20251,875.50 JPY
10/7/20251,903.00 JPY
10/6/20251,905.00 JPY
10/3/20251,784.00 JPY
10/2/20251,779.00 JPY
10/1/20251,826.00 JPY
9/30/20251,824.50 JPY
9/29/20251,829.00 JPY
9/26/20251,824.50 JPY
9/25/20251,836.00 JPY
9/24/20251,850.50 JPY
9/22/20251,867.00 JPY
9/19/20251,864.00 JPY
9/18/20251,910.00 JPY
9/17/20251,899.50 JPY
9/16/20251,885.50 JPY
9/12/20251,891.00 JPY
9/11/20251,894.00 JPY
9/10/20251,914.50 JPY
9/9/20251,911.50 JPY
9/8/20251,962.00 JPY
9/5/20251,952.50 JPY
9/4/20251,907.00 JPY
9/3/20251,902.50 JPY
9/2/20251,900.00 JPY
9/1/20251,884.00 JPY
8/29/20251,868.00 JPY
8/28/20251,893.00 JPY
8/27/20251,897.50 JPY
8/26/20251,909.00 JPY
8/25/20251,931.50 JPY
8/22/20251,968.00 JPY
8/21/20251,963.00 JPY
Access this data via the Eulerpool API
Get Free API Key

Sysmex Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2023
410.50 B JPY
73.99 B JPY
45.78 B JPY
Jan 1, 2024
461.51 B JPY
80.06 B JPY
49.64 B JPY
Jan 1, 2025
508.64 B JPY
90.35 B JPY
53.67 B JPY
Jan 1, 2026 (e)
498.17 B JPY
78.24 B JPY
39.94 B JPY
Jan 1, 2027 (e)
536.49 B JPY
84.25 B JPY
40.89 B JPY
Jan 1, 2028 (e)
566.33 B JPY
88.94 B JPY
48.26 B JPY
Jan 1, 2029 (e)
599.06 B JPY
94.08 B JPY
56.60 B JPY
Jan 1, 2030 (e)
635.47 B JPY
99.80 B JPY
64.84 B JPY

Sysmex Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 20, 2026, 8:38 PM
 
REVENUEB JPY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB JPY
EBITB JPY
EBIT MARGIN%
NET INCOMEB JPY
NET INCOME GROWTH%
DIV.JPY
DIV. GROWTH%
SHARESM
20162017201820192020202120222023202420252026e2027e2028e2029e2030e2031e
252.62249.90281.94293.51301.98305.07363.78410.50461.51508.64498.17536.49566.33599.06635.47669.97
14.11-1.0812.824.102.891.0219.2412.8412.4310.21-2.067.695.565.786.085.43
59.6556.7356.3855.0652.9250.5852.3952.6452.5453.4753.4753.4753.4753.4753.4753.47
150.69141.78158.95161.61159.81154.30190.59216.08242.50271.98266.38286.87302.82320.32339.79358.24
61.0851.9260.0161.4354.8949.8668.9573.9980.0690.3578.2484.2588.9494.0899.80105.22
24.1820.7721.2920.9318.1816.3418.9518.0317.3517.7615.7015.7015.7015.7015.7015.70
39.2840.6439.2241.2234.8831.9144.0945.7849.6453.6739.9440.8948.2656.6064.8469.25
47.453.46-3.485.10-15.38-8.5438.203.848.428.12-25.582.3718.0217.2814.576.80
56.0060.0064.0072.0072.0073.0079.0082.0029.0035.0055.0064.9276.63–––
33.337.146.6712.50–1.398.223.80-64.6320.6957.1418.0418.04–––
625.78626.01626.42626.87626.93627.77628.43627.97626.43623.53623.53623.53623.53623.53623.53623.53
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sysmex generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sysmex retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sysmex's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sysmex has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sysmex's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sysmex stock margins

The Sysmex margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sysmex. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sysmex.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2021
50.58 %
16.34 %
10.46 %
Jan 1, 2022
52.39 %
18.95 %
12.12 %
Jan 1, 2023
52.64 %
18.03 %
11.15 %
Jan 1, 2024
52.54 %
17.35 %
10.76 %
Jan 1, 2025
53.47 %
17.76 %
10.55 %
Jan 1, 2026 (e)
53.47 %
15.70 %
8.02 %
Jan 1, 2027 (e)
53.47 %
15.70 %
7.62 %
Jan 1, 2028 (e)
53.47 %
15.70 %
8.52 %

Sysmex Stock Revenue, EBIT, Earnings per Share

The Sysmex earnings per share therefore indicates how much revenue Sysmex has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2021
485.97 JPY
79.43 JPY
50.82 JPY
Jan 1, 2022
578.87 JPY
109.72 JPY
70.16 JPY
Jan 1, 2023
653.70 JPY
117.83 JPY
72.91 JPY
Jan 1, 2024
736.74 JPY
127.80 JPY
79.24 JPY
Jan 1, 2025
815.74 JPY
144.90 JPY
86.07 JPY
Jan 1, 2026 (e)
798.95 JPY
125.47 JPY
64.06 JPY
Jan 1, 2027 (e)
860.41 JPY
135.12 JPY
65.57 JPY
Jan 1, 2028 (e)
908.26 JPY
142.64 JPY
77.39 JPY

Sysmex business model & stock analysis

Sysmex Corp is a Japanese company that has been a leading provider of diagnostic and analytical laboratory systems and solutions for the healthcare industry since its founding in 1968. The company is headquartered in Kobe, Japan and employs over 9,000 people worldwide. History: Sysmex was founded by a group of young scientists in Japan who wanted to develop an automated blood cell analysis system to improve the high workload of manual blood analysis at the time. The company began developing this system and brought it to market in 1972. Business model: Sysmex focuses on the development, production, and sale of diagnostic systems and solutions for medical laboratories around the world. The company specializes in hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology. Divisions: Sysmex Corp is divided into three main business divisions: 1. Diagnostic Systems: This division includes hematology, hemoglobinopathy, hemostasis, urinalysis, immunology, clinical chemistry, and molecular biology systems. Sysmex is one of the world's leading providers of hematology analysis devices and also offers molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. 2. Information Solutions: This division offers software and IT solutions that support laboratory management and the integration of laboratory data to optimize analysis processes. The company also offers solutions for automating laboratory processes and managing laboratory inventory. 3. Life Science: This division focuses on the development of products for the life sciences, particularly cell analysis and imaging, as well as production, processing, and storage of cell cultures. Sysmex is also involved in the production of devices for harvesting mesenchymal stem cells from adipose tissue. Products: Sysmex offers a variety of products, including: - Hematology analysis devices for determining blood cell parameters such as RBC, WBC, HGB, HCT, and platelets. - Hemostasis systems for analyzing blood coagulation. - Molecular biology systems for the diagnosis and monitoring of infectious diseases and cancer. - Urinalysis systems for analyzing urine samples for chemical and microscopic parameters. - Immunology analysis devices for determining specific proteins and antibodies in the blood. - Clinical chemistry analysis devices for analyzing chemical parameters in blood samples. - Software and IT solutions for optimizing laboratory processes and management. - Cell analysis and imaging systems for investigating cell morphology and functions. - Devices for harvesting mesenchymal stem cells from adipose tissue. In summary, Sysmex Corp is a global leader in diagnostic and analytical laboratory systems and solutions for the healthcare industry. In its nearly 50-year history, the company has developed and produced a wide range of products that enable laboratories to perform fast and accurate disease diagnosis. The company has also expanded its business into other areas such as information solutions and the life sciences.

Sysmex SWOT Analysis

Strengths

Sysmex Corp is renowned for its advanced medical technology and laboratory testing equipment. This gives the company a competitive advantage in providing cutting-edge diagnostic solutions to healthcare providers worldwide.

With a wide distribution network and well-established subsidiaries in numerous countries, Sysmex Corp has a strong international presence. This allows the company to serve a diverse customer base and explore new market opportunities.

Sysmex Corp invests significantly in research and development, enabling continuous innovation in the medical diagnostics field. This enables them to introduce new products and stay ahead of competitors.

Weaknesses

Sysmex Corp heavily relies on a few key products, which could pose a risk if there is a decline in demand or potential product obsolescence. Diversification of their product portfolio might mitigate this risk.

As a healthcare company, Sysmex Corp operates in a highly regulated industry. Changes in regulations or policies can impact their operations, requiring constant adaptation and compliance efforts.

Opportunities

The increasing healthcare needs of the global population present significant growth opportunities for Sysmex Corp. They can expand their reach and offer innovative solutions to address emerging health challenges.

Sysmex Corp can venture into untapped markets, especially in emerging economies where demand for advanced medical diagnostics is rising. This would help them diversify their customer base and increase revenue streams.

Threats

Sysmex Corp faces strong competition from major players in the medical diagnostics industry. Competitors with similar product offerings and well-established market presence can potentially challenge Sysmex Corp's market share.

Economic downturns or financial instability can affect the healthcare industry, leading to reduced healthcare spending and potential customer budget constraints. Sysmex Corp needs to be prepared to navigate such challenges.

Sysmex Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sysmex historical P/E ratio, EBIT multiple, and P/S ratio

Sysmex annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sysmex shares outstanding

The number of shares of Sysmex was 623.53 M in 2025. This indicates how many shares Sysmex is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2021
627.77 M Stocks
Jan 1, 2022
628.43 M Stocks
Jan 1, 2023
627.97 M Stocks
Jan 1, 2024
626.43 M Stocks
Jan 1, 2025
623.53 M Stocks
Jan 1, 2026 (e)
623.53 M Stocks
Jan 1, 2027 (e)
623.53 M Stocks
Jan 1, 2028 (e)
623.53 M Stocks

Sysmex stock splits

In Sysmex's history, there have been no stock splits.

Sysmex Dividend History

33 years of dividend payments

YearAnnual DividendYoY ChangePayments
202618.00JPYYTD—1×
Mar 30, 202618.00JPY 0.0%1/1
202535.00JPY↑ 20.7%2×
Mar 28, 202517.00JPY↑ 13.3%1/2
Sep 29, 202518.00JPY↑ 5.9%2/2
202429.00JPY↓ 64.6%2×
202382.00JPY↑ 3.8%2×
202279.00JPY↑ 8.2%2×
202173.00JPY↑ 1.4%2×
202072.00JPY 0.0%2×
201972.00JPY↑ 12.5%2×
201864.00JPY↑ 6.7%2×
201760.00JPY↑ 7.1%2×

Sysmex dividend history and estimates

In 2025, Sysmex paid a dividend amounting to 35.00 JPY. Dividend means that Sysmex distributes a portion of its profits to its owners.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Dividend
Details
Date
Dividend
Dividend (Estimate)
Jan 1, 2021
73.00 JPY
0.00 JPY
Jan 1, 2022
79.00 JPY
0.00 JPY
Jan 1, 2023
82.00 JPY
0.00 JPY
Jan 1, 2024
29.00 JPY
0.00 JPY
Jan 1, 2025
35.00 JPY
0.00 JPY
Jan 1, 2026
55.00 JPY
0.00 JPY
Jan 1, 2027 (e)
0.00 JPY
64.92 JPY
Jan 1, 2028 (e)
0.00 JPY
76.63 JPY

Sysmex dividend payout ratio

In 2025, Sysmex had a payout ratio of 41.83%. The payout ratio indicates the percentage of the company's profits that Sysmex distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2021
47.88 %
Jan 1, 2022
37.53 %
Jan 1, 2023
38.40 %
Jan 1, 2024
36.60 %
Jan 1, 2025
41.83 %
Jan 1, 2026 (e)
85.86 %
Jan 1, 2027 (e)
99.01 %
Jan 1, 2028 (e)
99.02 %

Current Sysmex forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
76.19 % (16)
Hold
23.81 % (5)
Sell
0.00 % (0)
12M Price Target
2,320.50
Last Price
1,919.50
Currency
JPY
12M Return Potential
20.89 %
LTM Return
0 %

Sysmex Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
5/9/202475.11JPY-126.36 BJPY-2024 Q4
2/7/202461.53JPY-115.61 BJPY-2024 Q3
5/10/2023134.91JPY-117.56 BJPY-2023 Q4
2/8/202353.59JPY-105.85 BJPY-2023 Q3
11/9/202221.96JPY-102.70 BJPY-2023 Q2
8/4/202246.82JPY-88.14 BJPY-2023 Q1
5/12/202254.05JPY-99.84 BJPY-2022 Q4
2/10/202256.88JPY-90.69 BJPY-2022 Q3
11/10/202132.94JPY-83.91 BJPY-2022 Q2
8/6/202136.67JPY-75.20 BJPY-2022 Q1

EESG©

Eulerpool ESG Scorecard© for the Sysmex stock

80/100
99
Environment
99
Social
41
Governance
E

Environment

20
Scope 1 - Direct Emissions13,925
Scope 2 - Indirect emissions from purchased energy6,706
Scope 3 - Indirect emissions within the value chain564,191
Total CO₂ emissions20,632
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees41.5
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sysmex shareholder structure

% Name
2.75464%
Nomura Asset Management Co., Ltd.
Nomura Asset Management Co., Ltd.
2.26777%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
1.97384%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
1.81236%
Harding Loevner LP
Harding Loevner LP
1.25377%
Daiwa Asset Management Co., Ltd.
Daiwa Asset Management Co., Ltd.
1.23747%
Nikko Asset Management Co., Ltd.
Nikko Asset Management Co., Ltd.
...

Sysmex Beneficial Ownership Filings (SEC 13D/G)

Free Float
70.6%
Float Shares
-
Shares Outstanding
-

Sysmex Executives and Management Board

25 members · avg. age 64 · 12 % women

HI

Mr. Hisashi Ietsugu (74)

Chairman of the Board, Group Chief Executive Officer, Representative Director · since 1986

242.00 M JPY

Management

KA

Mr. Kaoru Asano (65)

President, Representative Director · since 2009

221.00 M JPY
KT

Mr. Kenji Tachibana (66)

Senior Managing Executive Officer, Director · since 2011

121.00 M JPY
IM

Mr. Iwane Matsui (63)

Senior Managing Executive Officer, Director · since 2011

106.00 M JPY
TY

Mr. Tomokazu Yoshida (59)

Managing Executive Officer, Chief Technology Officer, Director · since 2017

–
TO

Mr. Takashi Ono (59)

Managing Executive Officer, Director · since 2019

–
FB

Mr. Frank Buescher

Senior Executive Officer

–

Board of Directors

TA

Mr. Tomoo Aramaki (57)

Director

–
YF

Ms. Yuka Fujioka (55)

Independent Director

–
KH

Mr. Kazumasa Hashimoto (70)

Independent Director

–
HI

Mr. Haruo Inoue (66)

Independent Director

–
MI

Mr. Michihide Iwasa (66)

Independent Director

–
KO

Mr. Kazuo Ota (69)

Independent Director

–

Sysmex Supply Chain

Sysmex Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
25 companies
#Nameβ 1YTrend
1
Medicover B
Customer·SE
0.69
0.78
0.64
0.89
0.77
0.76
—
2
Tecan Group
Supplier·Life Sciences Tools & Services·CH
-0.19
0.72
0.47
0.91
0.85
0.76
0.67
3
Integrated Diagnostics
Customer·Health Care Providers & Services·GB
-0.30
0.51
0.60
0.77
0.55
0.68
—
4
Surgical Science Sweden
Supplier·Health Care Equipment & Supplies·SE
0.75
0.63
-0.16
0.78
0.65
0.67
—
5
Siemens Healthineers
Customer·Health Care Equipment & Supplies·DE
0.76
0.60
0.32
0.92
0.62
0.65
0.32
#Nameβ 1YTrend
1
Human Metabolome Techs
Supplier·Customer·Life Sciences Tools & Services·JP
0.83
0.38
-0.06
0.55
0.42
-0.42
0.27
2
Maccura Biotechnology A
Customer·Life Sciences Tools & Services·CN
0.55
0.69
0.19
0.59
0.14
-0.42
—
3
Thalys Med Tech A
Customer·Biotechnology·CN
0.42
0.67
0.22
0.01
-0.27
-0.40
—
4
Genedrive
Supplier·Life Sciences Tools & Services·GB
0.83
0.90
-0.01
0.53
0.17
-0.34
—
5
OPTiM
Supplier·Customer·Software·JP
0.60
0.75
0.62
0.86
0.48
-0.26
0.43

Frequently asked questions about Sysmex

Sysmex Corp is a leading healthcare company specializing in diagnostic testing equipment and technologies. The business model of Sysmex Corp revolves around the design, development, and manufacture of innovative testing systems for clinical laboratories and healthcare institutions. With a strong focus on hematological analysis and hemostasis, Sysmex Corp provides highly accurate and reliable diagnostic solutions to support disease detection, monitoring, and treatment. By leveraging advanced technologies and automation, the company enables efficient and precise diagnostic processes, ultimately contributing to better patient outcomes. Sysmex Corp's business model centers on delivering cutting-edge diagnostic solutions that empower healthcare professionals with the tools they need for accurate and timely diagnoses.

Sysmex Corp is primarily active in the healthcare and medical technology industries.

The main competitors of Sysmex Corp in the market include Abbott Laboratories, Siemens Healthineers, and Becton, Dickinson and Company (BD).

Sysmex Corp is a renowned healthcare company specializing in diagnostic solutions for medical organizations. Founded in 1968, Sysmex Corp has since achieved global recognition for its advanced technologies and commitment to improving medical diagnoses and treatments. The company offers a wide range of innovative products, including automated clinical laboratory systems, reagents, and software. Sysmex Corp has established itself as a leader in the field of blood and urinalysis testing, leveraging cutting-edge research and partnerships to enhance patient care. With a rich history spanning several decades, Sysmex Corp continues to revolutionize the healthcare industry with its strategic advancements and dedication to improving medical outcomes worldwide.

Sysmex Corp has achieved several significant milestones throughout its history. Some of these achievements include the development of the world's first automated blood coagulation analyzer, the introduction of the first fully automated urine sediment analyzer, and the establishment of international subsidiaries to expand its global presence. Sysmex Corp has also made advancements in the field of hematology, with the production of automated blood cell analyzers that provide accurate and efficient results. Additionally, the company has received recognition for its contributions to healthcare, such as the Japan Medical Device Excellence Award. Overall, Sysmex Corp's commitment to innovation and quality has led to various notable milestones in the medical technology industry.

Sysmex Corp is primarily present in various countries and regions across the globe. Some of the key markets where Sysmex Corp has a significant presence include Japan, the company's home country, where it is headquartered. Sysmex Corp also has a strong foothold in the Asia-Pacific region, particularly in China, South Korea, and India. Furthermore, Sysmex Corp has expanded its operations and established a notable presence in North America, primarily in the United States. Additionally, Sysmex Corp has a growing presence in Europe, with key markets such as Germany, France, and the United Kingdom.

Sysmex Corp represents values of integrity, innovation, and collaboration. With a strong corporate philosophy that revolves around contributing to the advancement of healthcare, Sysmex Corp is committed to providing reliable and efficient diagnostic solutions. The company prioritizes sustainable growth, social responsibility, and customer satisfaction. Through their cutting-edge technologies and solutions in the field of laboratory testing, Sysmex Corp aims to improve patient outcomes and enhance overall healthcare globally. With their dedication to excellence and continuous improvement, Sysmex Corp has established itself as a trusted leader in the healthcare industry.

Analysts currently set an average price target of 2,391.26 JPY for the Sysmex stock (median: 2,320.50 JPY), implying +24.6 % versus the latest price. The consensus is based on 21 analyst ratings.

Sysmex Analyst Price Targets 2026

21 analysts currently rate the Sysmex stock: 16 recommend buying, 5 holding and 0 selling. For 2026, analysts expect Sysmex to generate revenue of 498.17 B JPY and earnings per share of 64.06 JPY.

Sysmex Analyst Price Targets 2026

Converted at the current exchange rate, the Sysmex share trades at 10.27 EUR (1,897.50 JPY).

The Sysmex share (6869.T) is listed on 4 stock exchanges, including: Frankfurt (0YX.F), München (0YX.MU).

Sysmex Corp is a Japanese manufacturer of medical diagnostic devices and systems. The company is a global leader in the development and production of hematology and urine analysis devices, coagulation analysis devices, immunoassay systems, cell imaging devices, and laboratory automation solutions. The company is divided into three business segments: Diagnostic Business, Life Science Business, and IT Business. The Diagnostic Business focuses on the development and production of hematology and urine analysis devices and coagulation analysis devices, which are used in various medical fields such as hematology, oncology, pediatrics, and intensive care medicine. The Life Science Business includes immunoassay systems, cell imaging devices, and laboratory automation solutions, which are used in research and development, diagnostics, and drug development. The IT Business provides IT-based solutions for the medical fields served by the other business segments, aiming to efficiently collect and process data. Sysmex Corp is known for its research and development efforts, as well as its manufacturing capabilities, and it has established itself as an important player in the global healthcare industry. The company has a strong presence in international markets, with branches in over 190 countries. Sysmex Corp has partnerships with leading companies in the medical and pharmaceutical industries, allowing it to further strengthen and expand its position in the market. The company has a customer-oriented approach and strives to meet the needs of its clients. Overall, Sysmex Corp has revolutionized and modernized various medical fields with its unique products and services, making a significant contribution to the global healthcare industry.

The expected revenue of Sysmex is 498.17 B JPY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sysmex is 39.94 B JPY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sysmex is currently 29.62. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sysmex stock.

The price-to-sales ratio (P/S) of Sysmex is currently 2.38. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sysmex stock.

The Eulerpool Quality Score for Sysmex is 8/10.

The ISIN of Sysmex is JP3351100007. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Sysmex is 897966. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Sysmex is 6869.T. The ticker symbol is used to trade Sysmex shares on the stock exchange.

Over the past 12 months, Sysmex paid a dividend of 35.00 JPY . This corresponds to a dividend yield of about 1.84 %. For the coming 12 months, Sysmex is expected to pay a dividend of 64.92 JPY.

The current dividend yield of Sysmex is 1.84 %.

Sysmex pays a dividend, distributed in the months of , , , .

Sysmex paid dividends every year for the past 30 years.

For the upcoming 12 months, dividends amounting to 64.92 JPY are expected. This corresponds to a dividend yield of 3.42 %.

Sysmex is assigned to the 'Health' sector.

To receive the latest dividend of Sysmex from amounting to 18 JPY, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

In the year 2025, Sysmex distributed 28 JPY as dividends.

The dividends of Sysmex are distributed in JPY.

All fundamentals and in-depth analysis of Sysmex

Our stock analysis for Sysmex stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sysmex. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sysmex Stock
Sysmex Revenue→
Sysmex Stock
Sysmex Net Income→
Sysmex Stock
Sysmex P/E→
Sysmex Stock
Sysmex P/S→
Sysmex Stock
Sysmex EBIT→
Sysmex Stock
Sysmex Dividend→
Sysmex Stock
Sysmex Directors Dealings→
Sysmex Stock
Sysmex Stocks→
Sysmex Stock
Sysmex Market capitalization→
Sysmex Stock
Sysmex Debt→
Sysmex Stock
Sysmex Liabilities→
Sysmex Stock
Sysmex Equity→
Sysmex Stock
Sysmex AAQS→
Sysmex Stock
Sysmex Employees→
Sysmex Stock
Sysmex ROE→
Sysmex Stock
Sysmex ROA→
Sysmex Stock
Sysmex ROCE→
Sysmex Stock
Sysmex News→
Sysmex Stock
Sysmex Analyst Price Targets→

Health Stocks

T&L CoSyschem (India)T&R Biofab CoSyros PharmaceuticalsT2 BiosystemsSyra HealthTactile Systems TechnologySyntheticMR AB (publ)Taigen Biopharmaceuticals HoldingsSynthaverseTaiko Pharmaceutical CoSyntekaBioAll Stocks A–Z →